StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

POLYMED — POLY MEDICURE LIMITED

Structural concernsWeak profitabilityInstitutions reducing stake

Price History

Data as of 26 Jun 2026· via fincrux

How POLYMED has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Middle of its 12-month range43% of range

Sitting roughly mid-way between its 12-month high and low — neither cheap nor stretched versus its own recent history. It sits right around its 200-day average.

₹1,191 low₹2,266 high
vs 50-day avg
+9.6%
vs 200-day avg
+0.3%
Beginner mode
Plain English, with everything explained

POLYMED

NSE

POLY MEDICURE LIMITED

Healthcare / Equipment

₹1,650.20
0.00%
last close
0%
Quality Score
Several red flagsBig money selling

POLY MEDICURE LIMITED clears only 1 of 3 checks. The numbers flag real concerns — exactly the kind of thing that gets lost in exciting news or social-media buzz. Tread carefully.

Company size
₹13680.00 Cr
Price tag
40.1×
Money it earns
11.8%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.08goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Divergent

Profits relative to the money invested are on the weaker side over the last few years.

ROE 11.8%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Divergent

Professional investors have been reducing their stake recently.

FII+DII 21.5%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What POLYMED owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings111137164172252
Equity Capital4848485151
Reserves1,0291,1861,4102,6943,002
Total Assets1,3341,5381,8213,1403,550
Total Liabilities1,3341,5381,8213,1403,550

Borrowings rising

Total borrowings are up about 127% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for POLYMED — does it earn money consistently?

Consistently profitable

Every one of the last 5 years has been profitable — a sign of durable earnings.

₹146 Cr
₹179 Cr
₹252 Cr
₹331 Cr
₹336 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹879 Crrev ₹1,068 Crrev ₹1,306 Crrev ₹1,601 Crrev ₹1,662 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about POLYMED — observations, not recommendations.

Strengths

2
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Profitable in every one of the last 5 years.

Risks

2
  • Profit generated from the money invested has been on the weaker side.
  • Large professional investors have been trimming their stake recently.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
5.9%-5.5 pp
DII· Domestic institutions
15.6%+3.9 pp
Jun '25Sep '25Dec '25Mar '26